Reset
Re-establishing the baseline.
Tissue Repair and Inflammatory Resolution
How does the body return injured connective tissue and inflamed microenvironments to a stable baseline?
The Reset phase organizes literature describing the earliest stages of recovery: hemostasis, controlled inflammation, and the resolution signals that close acute tissue injury.
Investigated mechanisms include angiogenic activity, fibroblast migration, and cytokine modulation across gastrointestinal, tendon, ligament, and musculoskeletal models.
Research in this domain has been described primarily in preclinical and animal models, with translational hypotheses discussed in subsequent investigational literature.
- BPC-157
Pentadecapeptide studied in connective tissue, gastrointestinal, and vascular repair models.
- TB-500 (Thymosin Beta-4 fragment)
Investigated for actin sequestration, cellular migration, and soft-tissue remodeling.
| Short Trial | Standard Trial | Extended Trial | |
|---|---|---|---|
| Research Period | 2 weeks | 4 weeks | 8 weeks |
| Research Schedule | Once daily | Once daily | Twice weekly |
| Research Dose | 0.25 mg (5 units) | 0.5 mg (10 units) | 0.5 mg (10 units) |
| Total Research Material | 10 mg (200 units) | 20 mg (400 units) | 20 mg (400 units) |
| Research Vials Needed | 1 × 10 mg vial | 2 × 10 mg vial | 2 × 10 mg vial |
Standardized educational reference: 10 mg vial reconstituted with 2 mL bacteriostatic water (5 mg per mL; 0.05 mg per unit on a 100-unit insulin reference scale).
Research Note: The majority of published BPC-157 and TB-500 investigations have been conducted in animal models rather than human clinical trials.
Once baseline tissue integrity is re-established, the literature describes the next biological domain — cellular and dermal restoration.
For Research Use Only
Not for Human Consumption.
Describe. Never Prescribe.